Shuangshen granules

  • 文章类型: Journal Article
    背景:基于拟议的肺-肠轴,菌群与肺转移有显著的相关性。靶向微生物组合物在调节宿主对癌症治疗剂的应答中是有价值的。作为中药(TCM)配方,双参颗粒(SSG)在临床上对延缓肺转移、但其潜在机制仍然未知。
    方法:选择C57BL/6N小鼠建立Lewis肺癌模型。建立广谱抗生素(ABX)组以评估微生物群组成对转移的影响。通过组织病理学研究不同剂量SSG治疗肺转移的疗效。免疫组织化学,和Westernblot分析方法。此外,通过流式细胞术评估肺和血液中肿瘤相关巨噬细胞(TAMs)的表型.还设计了粪便微生物群移植(FMT)和阴性对照(ABX加高剂量SSG组)实验,以评估肠道微生物群在SSG干预肺转移结局中的作用。使用16SrRNA扩增子测序和非靶向代谢组学分析来分析患有肺转移的荷瘤小鼠中由SSG介导的肠道微生物群和代谢物变化。
    结果:ABX可观察到导致肠道菌群失调并增强转移。SSG对肺转移有明显的化学预防作用,转移结节减少和转移前生态位生物标志物的表达水平,富集了CD86+F4/80+CD11b+细胞的比例,而FMT延迟转移相似。对微生物群和代谢产物的分析表明,SSG显著富集了粪便中的益生菌,包括Akkermansiamuciniphila,LachnosclostridiumspYL32,Limosilactobacillusreuteri,和潜在的抗癌血清代谢物,包括人参皂苷Rb1,异喹啉,Betulin等。我们还研究了SSG对肺转移的保护机制,并表明SSG调节微生物群,改进的TAM极化,并抑制NF-κB通路的表达。
    结论:我们文章中的结果表明,SSG通过减轻荷瘤小鼠的肠道菌群失衡和代谢紊乱,改善TAMs极化并抑制NF-κB通路,导致肺转移延迟。
    BACKGROUND: Based on the proposed lung-intestinal axis, there is a significant correlation between the microbiota and lung metastasis. Targeting the microbial composition is valuable in modulating the host response to cancer therapeutics. As a traditional Chinese medicine (TCM) formula, Shuangshen granules (SSG) are clinically useful in delaying lung metastasis, but its underlying mechanisms remain unknown.
    METHODS: The C57BL/6N mice were chosen to establish the Lewis lung cancer models. The broad-spectrum antibiotics (ABX) group was set up to estimate the effect of microbiota composition on metastasis. The therapeutic effects of different doses of SSG in treating lung metastasis were investigated through histopathology, immunohistochemistry, and Western blot analysis methods. Additionally, the phenotype of tumor-associated macrophages (TAMs) in the lung and blood was evaluated by flow cytometry. The fecal microbiota transplantation (FMT) and negative control (ABX plus high dose SSG group) experiments were also designed to assess intestinal microbiota\'s role in SSG intervention\'s outcome in lung metastasis. The 16S rRNA amplicon sequencing and Untargeted metabolomic analysis were used to analyze intestinal microbiota and metabolite changes mediated by SSG in tumor-bearing mice with lung metastasis.
    RESULTS: ABX could observably lead to intestinal microbiota dysbiosis and enhance metastasis. SSG showed a significant chemopreventive effect in lung metastasis, reduced metastatic nodules and the expression levels of pre-metastatic niche biomarkers, and enriched the ratio of CD86+F4/80+CD11b+ cells, while FMT delayed metastasis similarly. The analysis of microbiota and metabolites revealed that SSG significantly enriched probiotics in feces, including Akkermansia muciniphila, Lachnoclostridium sp YL32, Limosilactobacillus reuteri, and potential anti-cancer serum metabolites, including Ginsenoside Rb1, Isoquinoline, Betulin and so on. We also investigated the mechanism of SSG protection against lung metastasis and showed that SSG regulated microbiota, improved TAMs polarization, and inhibited the expression of the NF-κB pathway.
    CONCLUSIONS: The results presented in our article demonstrated that SSG improved TAMs polarization and inhibited the NF-κB pathway by alleviating intestinal microbiota imbalance and metabolic disorders in tumor-bearing mice, resulting in delayed lung metastasis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:双参颗粒(SSG),国家专利的中药配方,包括西洋参,三七(伯基尔)F.H.Chen,和冬虫夏草(Berk。)萨克。,在近10年的临床治疗中对胰腺癌有显著的治疗效果。以往的药理研究发现,其主要成分,包括人参皂苷和虫草素对胰腺导管腺癌(PDAC)具有抗癌或预防作用,这可能与免疫代谢有关。然而,SSG在PDAC进展的截断效应中的潜在药理机制尚不清楚。
    目的:全面了解PDAC发育链不同阶段的浸润免疫细胞,并通过生物信息学分析寻找可能作为药物靶标的免疫相关生物标志物。同时,还研究了SSG对PDAC进展的截断效应.
    方法:不同PDAC发育阶段的基因表达谱,包括正常的胰腺,胰腺上皮内瘤变(PanIN),PDAC,是从GEO数据库中检索的。GEO2R工具用于鉴定三组之间的差异表达基因。用GSEA软件和Metascape平台进行功能富集分析。TheCIBERSORT算法评估了三组的免疫细胞浸润,并鉴定了免疫相关的生物标志物。采用相关性分析来检查免疫细胞与生物标志物之间的关联。选择这些生物标志物之一用于人样品中的免疫组织化学验证。最后,在体内验证了SSG对抗PDAC进展的有效性以及对所选生物标志物的影响.还探讨了潜在的药理机制。
    结果:获得了一个数据集,其中DEGs的功能富集主要涉及免疫效应子过程和免疫细胞的细胞因子产生。从PanIN到PDAC的过程中反映的差异免疫细胞是B记忆细胞,单核细胞,M2巨噬细胞,和激活的树突状细胞。ACTA2的上调与M2巨噬细胞的调控密切相关。人样品的免疫组织化学证实了随着PDAC进展ACTA2表达水平的显著差异。此外,动物实验表明,国家专利药物SSG改善了病理变化,PDAC过程中ACTA2及其功能蛋白α-平滑肌肌动蛋白的表达降低。潜在的药理机制与调节巨噬细胞极化和下调TGF-β/Smad信号通路有关。
    结论:在PDAC进展过程中,免疫抑制环境发生变化。ACTA2是PDAC药物预防的潜在免疫靶标,而SSG可能是一个有前途的候选药物。
    BACKGROUND: Shuangshen granules (SSG), a nationally patented Chinese medicinal formula, including Panax quinquefolium L., Panax notoginseng (Burkill) F. H. Chen, and Cordyceps sinensis (Berk.) Sacc., has demonstrated remarkable therapeutic effects on pancreatic cancer in clinical treatment for nearly 10 years. Previous pharmacological researches have found that its main components, including ginsenosides and cordycepin have anticancer or preventive effects on pancreatic ductal adenocarcinoma (PDAC), which may be associated with immune metabolism. However, the underlying pharmacological mechanism of SSG in the truncation effect of PDAC progression is still unclear.
    OBJECTIVE: To comprehensively understand the infiltrating immune cells during the different stages of the PDAC development chain and search for immune-related biomarkers that could potentially serve as drug targets through bioinformatic analysis. Meanwhile, the truncation effect of SSG on PDAC progression was also investigated.
    METHODS: The gene expression profiles at different PDAC developmental stages, including normal pancreas, pancreatic intraepithelial neoplasia (PanIN), and PDAC, were retrieved from the GEO database. The GEO2R tool was used to identify differentially expressed genes among the three groups. Functional enrichment analysis was performed with the GSEA software and Metascape platform. The CIBERSORT algorithm evaluated immune cell infiltration in the three groups, and immune-related biomarkers were identified. Correlation analysis was employed to examine the association between immune cells and the biomarkers. One of these biomarkers was selected for immunohistochemistry validation in human samples. Lastly, the effectiveness of SSG against PDAC progression and the influence on the selected biomarker were validated in vivo. The underlying pharmacological mechanisms were also explored.
    RESULTS: One dataset was obtained, where the functional enrichment of DEGs primarily involved immune effector processes and cytokine production of immune cells. The differential immune cells reflected during the progression from PanIN to PDAC were B memory cells, monocytes, M2 macrophages, and activated dendritic cells. The upregulation of ACTA2 was closely associated with M2 macrophage regulation. The immunohistochemistry on human samples validated significant differences in ACTA2 expression levels as the PDAC progressed. Moreover, animal experiments revealed that the national patented drug SSG ameliorated the pathological changes, decreased the expression of ACTA2 and its functional protein α-smooth muscle actin during PDAC progression. The underlying pharmacological mechanism was related to the regulation of macrophage polarization and downregulation of TGF-β/Smad signaling pathway.
    CONCLUSIONS: The immunosuppressive environment changes during the PDAC progression. ACTA2 is a potential immuned-target for drug prevention of PDAC, while SSG could be a promising drug candidate.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    BACKGROUND: Traditional Chinese medicine Shuangshen granules (SSG) have been used to treat lung cancer patients with Qi deficiency and blood stasis for decades. According to clinical experience, SSG indeed improve the quality of life and prolong the survival time of patients with lung cancer after surgery. Each of the components herbs was proved to be effective in anti-cancer therapy. Both the American ginseng and notoginseng belong to genus Panax of the family Araliaceae. Preclinical and clinical studies demonstrated that ginsenosides of them have anti- or preventive activities to various tumors, including cancers of gastric, breast, liver, lung, ovarian, colon, melanoma and leukemia. PDS, such as ginsenoside Rb1, and PTS, such as ginsenoside Rg1 are the main anticancer compositions. Cordyceps sinensis had also been found effective in inhibiting tumour growth and metastasis, especially on tumour associated immune cells, such as macrophages. However, limited information is available regarding potential mechanisms of SSG. Myeloid-derived suppressor cell (MDSC)-mediated immunosuppression, which is closely associated with poor clinical outcomes in cancer patients, may be the target of SSG, which regulate immune function.
    OBJECTIVE: The present study aimed to explore whether SSG attenuate the differentiation of bone marrow cells (BMCs) into MDSCs by blocking the mTOR signalling, leading to the suppression of lung metastasis.
    METHODS: First, we observed the differentiation of BMCs into MDSCs in vitro and in vivo. BMCs were cultured alone or co-cultured with Lewis lung carcinoma (LLC) cell supernatant in vitro. The effects of different concentrations of SSG, or LLC cell supernatant as a control, on BMC differentiation were detected by flow cytometry and western blotting. Male C57BL/6J mice were subcutaneously implanted with LLC cells, and SSG were administered by gavage twice daily before and after implantation for 7 or 14 days, respectively. The tumour weight, proportion of MDSCs, presence of CD11b+Ly6C+Ly6G- and CD11b+Ly6C+Ly6G+ cells in the bone marrow, blood, and lungs, as well as the expression levels of differentiation-related proteins in the bone marrow and lungs were evaluated.
    RESULTS: SSG attenuated the differentiation of BMCs into MDSCs, and reduced the fraction of CD11b+Ly6C+Ly6G+ cells by inhibiting the mTOR/S6K1/Myc signalling pathway. In vivo, SSG attenuated differentiation-associated protein markers and reduced the fractions of MDSCs and CD11b+Ly6C+Ly6G+ cells in the bone marrow, blood, and lungs. In addition, SSG administration reduced the tumour weight and inhibited lung metastasis.
    CONCLUSIONS: SSG may reduce lung metastasis by attenuating BMC differentiation into CD11b+Ly6C+Ly6G+ cells by inhibiting mTOR signalling in vitro and in vivo.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号